MedWorm: Avastin

  Avastin fight now moves to P.E.I.

A cancer patient who successfully helped lobby the New Brunswick government to fund an expensive cancer drug is now shifting his focus to P.E.I. in an effort to have Avastin funded by that province. (Source: CBC | Health)

top  

  Anti-AMD Drug Use Stirs Concern in Canada (CME/CE)

Intravitreal drug injections for age-related macular degeneration in at least one Canadian province have mushroomed in recent years, likely adding fuel to a controversy over off-label use of bevacizumab for this purpose. (Source: MedPage Today Public Health)

top  

  Macular ischaemia after intravitreal bevacizumab injection in patients with central retinal vein occlusion and a history of diabetes and vascular disease

(Source: British Journal of Ophthalmology)

top  

  Pemetrexed Plus Bevacizumab for Second-Line Therapy of Non-Small-Cell Lung Cancer: The Importance of Patient Selection [CORRESPONDENCE]

(Source: Journal of Clinical Oncology)

top  

  Rapid Expansion of Intravitreal Drug Injection Procedures, 2000 to 2008: A Population-Based Analysis [Socioeconomics and Health Services]

Conclusions  The development of vascular endothelial growth factor inhibitors has revolutionized the treatment of age-related macular degeneration. To our knowledge, this study is the first to quantify the dramatic uptake of these treatments at a population level. Our findings also suggest that off-label injection of bevacizumab was highly prevalent in Ontario. Serial intravitreal injections requiring direct physician administration and the concentration of injection procedures in the hands of a small number of ophthalmologists have the potential to affect services for other vision-threatening conditions. (Source: Archives of Opthalmology)

top  

  Bevacizumab for Malignant Gliomas [Neurological Review]

Malignant gliomas are the most common and aggressive primary brain tumors in adults. Despite optimal treatment with surgery, radiotherapy, and temozolomide, tumor recurrences are frequent and patients with malignant gliomas continue to have poor prognoses. Malignant gliomas are often highly vascularized, and significant advances have been made in the last few decades in our understanding of the mechanisms of tumor angiogenesis. Recently, bevacizumab, an antibody against vascular endothelial growth factor, has demonstrated significant activity in recurrent glioblastomas, resulting in US Food and Drug Administration approval and raising the prospect for other antiangiogenic drugs now entering clinical trials. (Source: Archives of Neurology)

top  

  Recentin Did Not Meet Primary Endpoint in Horizon III Study in Metastatic Colorectal Cancer

This study,... (Source: Drugs.com - Clinical Trials)

top  

  RECENTIN Did Not Meet Primary Endpoint In Horizon III Study In Metastatic Colorectal Cancer

AstraZeneca recently announced the top-line results of a Phase II/III study evaluating RECENTIN (cediranib) compared with Avastin (bevacizumab) in patients with first-line metastatic colorectal cancer (mCRC). (Source: Pharmaceutical Online News)

top  

  Cancer drug may help treat chronic nosebleeds

Dr. Davidson is testing a new approach to treatment of HHT. He's using the cancer drug Avastin in low doses in both injection and spray forms to stop the nosebleeds.03/05/2010 (Source: Kidney Cancer Association)

top  

  Gynecologic Oncology Group Notifies CTI That Continuation Of GOG-212 Pivotal Trial Of OPAXIO Maintenance Therapy In Ovarian Cancer Is A Priority

Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: CTIC) announced that CTI received a statement on March 1, 2010 from the Gynecologic Oncology Group (GOG) leadership that the phase III GOG-212 clinical trial of CTI's OPAXIO™ used as maintenance therapy for ovarian cancer remains a high priority and enrollment will continue. The GOG made the statement to clarify that the recent results of the GOG-218 clinical trial bevacizumab in maintenance therapy for ovarian cancer has not influenced the importance of completing the GOG-212 clinical trial... (Source: Health News from Medical News Today)

top  

  Visceral fat area is an independent predictive biomarker of outcome after first-line bevacizumab-based treatment in metastatic colorectal cancer

Conclusion This study provides the first evidence that high VFA independently predicts a poorer outcome in patients given first-line bevacizumab-based treatment for MCC. However, this predictive biomarker needs to be validated in a different dataset. (Source: Gut)

top  

  Body fatness and bevacizumab-based therapy in metastatic colorectal cancer

(Source: Gut)

top  

  [Outlook: Future therapy of renal cell carcinoma]

Authors: Bergmann L, Miller K Targeted therapies have fundamentally altered the therapy of metastatic renal cell carcinoma (mRCC). Sunitinib today is an internationally recommended reference standard in first-line therapy; other drugs such as Temsirolimus, Everolimus, Bevacizumab (in combination with Interferon-alpha) and Sorafenib are part of the therapeutic arsenal. Practitioners thus have now more and better therapeutic options at hand, leading to a significantly improved prognosis for mRCC patients. Numerous ongoing research activities aim at the improvement of the benefits of the new compounds in the metastatic situation or application earlier in the course of the disease. Key aspects of future development in RCC are the optimization of the current therapy options by developing ne...

top  

  [First-line therapy of metastatic renal cell carcinoma - update 2009]

Authors: Miller K Several molecular therapies have recently become available in first-line therapy of metastatic renal cell carcinoma (mRCC), thus marginalizing cytocine-based therapy. The primary aim of treatment in this situation is to delay progression with an increase in long-term life expectancy along with enhanced quality of life. At present, three new substances are available: Sunitinib, Temsirolimus, and - in combination with Interferon-alpha - Bevacizumab. To date, sufficient data is at hand for all drugs, which has resulted in a consolidation of therapeutic strategy. Selecting the best therapy is highly relevant in everyday practice, depending, among other things, on clinical evidence, guidelines, and the respective approval status. The prognostic score according to Motzer (M...

top  

  Oxaliplatin and capecitabine in the treatment of patients with recurrent or refractory carcinoma of unknown primary site

Despite the widespread use of oxaliplatin-based regimens for colorectal and other gastrointestinal cancers, there is surprisingly little information regarding their empiric use for the treatment of carcinoma of unknown primary site (CUP). In the current study, the combination of oxaliplatin and capecitabine in patients with recurrent and refractory CUP was examined.Patients with CUP who had received at least 1 previous chemotherapy regimen were treated with oxaliplatin (130 mg/m2 intravenously on Day 1) and capecitabine (1000 mg/m2 orally twice daily on Days 1-14). Treatment cycles were repeated every 21 days. Patients with objective response or stable disease after 2 cycles continued treatment for 6 cycles or until disease progression.Nine of 48 patients (19%) had objective responses to t...

top  

  mTOR pathway inhibition in renal cell carcinoma.

Authors: Pinto Marín A, Redondo Sánchez A, Espinosa Arranz E, Zamora Auñón P, Castelo Fernández B, González Barón M Renal cell carcinoma therapy has changed in a very significant way in the last few years. Up to 5 new agents have been developed, improving the results previously achieved with cytokine therapy. Bevacizumab, sorafenib, sunitinib, temsirolimus, and everolimus are now part of the therapeutic arsenal for this illness. Particularly, this has been the first tumoral type in which inhibition of mammalian target of rapamycin (mTOR) has proved its efficacy in phase III trials, either as first-line therapy for poor prognosis patients (temsirolimus, CCI-779) or as second-line therapy after failure of tyrosine-kinase inhibitors (everolimus, RAD001)....

top  

  Out-of-pocket payment and cost-effectiveness of XELOX and XELOX plus bevacizumab therapy: from the perspective of metastatic colorectal cancer patients in Japan

Conclusions  We clarified the out-of-pocket payment and cost-effectiveness of chemotherapy of MCRC patients in Japan. Our previous survey shows it is highly possible that many patients prefer to pay that incremental out-of-pocket payment to gain one additional QAPFS year. However, our cost-effectiveness analysis was not conducted from the perspective of society or healthcare payers. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s10147-010-0045-xAuthors Takeru Shiroiwa, The University of Tokyo Department of Drug Policy and Management, Graduate School of Pharmaceutical Sciences Yakugaku-toshokan 4F, 7-3-1 Hongo, Bunkyo-ku Tokyo 113-0033 JapanTakashi Fukuda, The University of Tokyo Department of Health Economics and Epidemiology Research, School of Pu...

top  

  Bevacizumab: Endophthalmitis following intravitreal injection: 3 case reports

(Source: Reactions)

top  

  Persistent Ocular Hypertension Following Intravitreal Bevacizumab and Ranibizumab Injections

Journal of Ocular Pharmacology and Therapeutics Feb 2010, Vol. 26, No. 1: 105-110. (Source: Journal of Ocular Pharmacology and Therapeutics)

top  

  Endoscopic placement of self-expandable metal stents for malignant colonic obstruction: long-term outcomes and complication factors

Conclusion: Colorectal SEMS placement is relatively safe and effective but with a complication rate of nearly 25%. Patient characteristics and technical variables appear to affect the outcome of SEMS therapy. (Source: Gastrointestinal Endoscopy)

top  

  New molecular targeted therapies integrated with radiation therapy in lung cancer.

Authors: Provencio M, Sánchez A, Garrido P, Valcárcel F Non-small-cell lung cancer (NSCLC) accounts for approximately 80%-85% of all cases of lung cancer; for patients with stage III disease, it accounts for approximately 40% of all cases. The treatment for unresectable stage III NSCLC is the combination of platinum-based chemotherapy and thoracic radiation. In this article, new targeted agents under investigation for possible integration into the combined therapy are reviewed. One of the most promising strategies is the inhibition of the epidermal growth factor receptor (EGFR) pathway. Radiation activates EGFR signaling, leading to radio-resistance by inducing cell proliferation and enhanced DNA repair. Several preclinical models have shown synergistic activity when cetuxima...

top  

  The role of anti-epidermal growth factor receptor and anti-vascular endothelial growth factor therapies in the treatment of non-small-cell lung cancer.

Authors: Langer C, Soria JC Standard first-line therapy for non-small-cell lung cancer (NSCLC) with platinum-based agents, given in combination with cytotoxic compounds, has reached a relative plateau in its therapeutic efficacy. Novel molecular targeted agents acting on specific pathways have emerged as effective agents for treating NSCLC; some have already produced positive results in phase III trials. Notably, inhibition of the vascular endothelial growth factor (VEGF) pathway with an anti-VEGF antibody, bevacizumab, and targeting the epidermal growth factor receptor (EGFR) pathway with a small-molecule EGFR tyrosine kinase inhibitor erlotinib or a monoclonal antibody (cetuximab) have demonstrated prolonged survival in patients with advanced disease in both the first- and second-lin...

top  

  Avastin Phase III Study Shows Positive Results In Women With Advanced Ovarian Cancer

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that a phase III study showed the combination of Avastin (bevacizumab) and chemotherapy followed by maintenance use of Avastin increased the time women with advanced ovarian cancer lived without their disease worsening (progression-free survival or PFS) compared to chemotherapy alone. A preliminary assessment of safety noted adverse events previously observed in pivotal trials with Avastin. Data from the study will be submitted for presentation at the 2010 American Society of Clinical Oncology (ASCO) annual meeting, June 4 to 8, 2010... (Source: Health News from Medical News Today)

top  

  Avastin Phase III Study Shows Positive Results In Women With Advanced Ovarian Cancer

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that a phase III study showed the combination of Avastin (bevacizumab) and chemotherapy followed by maintenance use of Avastin increased the time women with advanced ovarian cancer lived without their disease worsening (progression-free survival or PFS) compared to chemotherapy alone... (Source: Pharma Industry News From Medical News Today)

top  

  Current Status and Problems in Development of Molecular Target Agents for Gastrointestinal Malignancy in Japan

Since late 1990s, many molecular target agents have been introduced to clinical trials for various kinds of tumors, and some of them showing significant benefits have been approved. However, these global trials were mainly conducted outside Japan, and the ‘drag lag’ has been a serious problem in Japan recently. Nowadays, Japanese institutions have been participating in some global trials, and the drug lags are getting shorter. For colorectal cancer, molecular target agents such as bevacizumab and cetuximab have been approved in Japan, resulting in improved clinical outcomes. For gastric cancer, Japanese institutions not only contribute to the global Phase III trials of trastuzumab and bevacizumab but also show leadership in the early development of other new agents. For pancrea...

top  

  Intravitreal bevacizumab for choroidal neovascular membrane associated with Best's vitelliform dystrophy

Rishi Ekta, Rishi Pukhraj, Mahajan SheshadriIndian Journal of Ophthalmology 2010 58(2):160-162Best's vitelliform macular dystrophy is a hereditary form of progressive macular dystrophy that can be complicated by choroidal neovascularization. Authors report successful treatment of choroidal neovascularization with intravitreal bevacizumab in one such eye in an 'adult' Indian male with visual improvement. A 23-year-old male presented with diminution of vision in the right eye for the past sixteen months. Visual acuity was 20/400 in the that eye. After three consecutive intravitreal injections of bevacizumab (1.25 mg/0.05 ml), vision improved to 20/120. Seven months following the last injection of bevacizumab, fundus appeared stable and visual acuity was maintained. No dr...

top  

  Pneumatic displacement and intravitreal bevacizumab for management of submacular hemorrhage in choroidal neovascular membrane

Agarwal Manisha, Chaudhary S P, Narula Ritesh, Rajpal SimpyIndian Journal of Ophthalmology 2010 58(2):170-171 (Source: Indian Journal of Ophthalmology)

top  

  Avastin "treats ovarian cancer"

A drug designed to stop tumours developing blood vessels could help women with advanced ovarian cancer live longer, preliminary tests suggest. (Source: Pharmacy Europe)

top  

  Bevacizumab Slows Ovarian Cancer Progression

Maintenance therapy with bevacizumab (Avastin) following combination therapy with the drug and chemotherapy improved progression-free survival in women with previously untreated advanced ovarian cancer, drugmaker Genentech announced. (Source: MedPage Today Hematology/Oncology)

top  

  Genentech Announces Positive Results Of Avastin Phase III Study In Women With Advanced Ovarian Cancer

Genentech, Inc., a wholly owned member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced that a Phase III study showed the combination of Avastin® (bevacizumab) and chemotherapy followed by maintenance use of Avastin alone increased the time women with previously untreated advanced ovarian cancer lived without the disease worsening (progression-free survival or PFS), compared to chemotherapy alone. A preliminary assessment of safety noted adverse events previously observed in pivotal trials of Avastin... (Source: Health News from Medical News Today)

top  

  Genentech Announces Positive Results Of Avastin Phase III Study In Women With Advanced Ovarian Cancer

Genentech, Inc... (Source: Cancer / Oncology News From Medical News Today)

top  

  Pharmacokinetics of Bevacizumab and Its Effect on Vascular Endothelial Growth Factor after Intravitreal Injection of Bevacizumab in Macaque Eyes [Physiology and Pharmacology]

The authors evaluated the pharmacokinetics of bevacizumab and its effect against vascular endothelial growth factor (VEGF) after intravitreal injection of bevacizumab in cynomolgus macaques. Intravitreal injection of bevacizumab decreased VEGF levels in the treated eyes for at least 4 weeks and had no or a minimal effect on the untreated fellow eyes. (Source: Investigative Ophthalmology)

top  

  Phase III study of Avastin in advanced stomach cancer did not meet primary endpoint

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the topline results from a global phase III trial investigating the use of Avastin (bevacizumab) in combination with Xeloda (capecitabine) or fluorouracil and cisplatin chemotherapy in patients with inoperable, advanced or metastatic gastric cancer (stomach cancer). (Source: World Pharma News)

top  

  Genentech: Avastin strong in ovarian cancer trial

Genentech Inc.’s cancer drug Avastin helped ovarian cancer patients live longer without the disease worsening, according to a preliminary assessment of a Phase III trial. (Source: bizjournals.com Health Care:Biotechnology headlines)

top  

  Genentech Announces Positive Results of Avastin Phase III Study in Women with Advanced Ovarian Cancer

First Phase III Study of an Anti-Angiogenic Therapy in Advanced Ovarian Cancer to Meet Primary Endpoint       SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Feb 25, 2010 - Genentech, Inc., a wholly owned member of the Roche... (Source: Drugs.com - Clinical Trials)

top  

  Genentech Announces Positive Results of Avastin Phase III Study in Women with Advanced Ovarian Cancer

First Phase III Study of an Anti-Angiogenic Therapy in Advanced Ovarian Cancer to Meet Primary Endpoint SOUTH SAN FRANCISCO, Calif.--(HSMN NewsFeed)--Genentech, Inc., a wholly owned member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced... Biopharmaceuticals, OncologyGenentech, Roche Group, Avastin, bevacizumab, ovarian cancer (Source: HSMN NewsFeed)

top  

  Roche's Avastin helps in ovarian cancer

ZURICH (Reuters) - Roche's Avastin helps women with advanced ovarian cancer live longer without their disease getting worse, a late-stage study showed, boosting its prospects after a recent setback in stomach cancer. (Source: Reuters: Health)

top  

  Avastin Shows Positive Results in Ovarian Cancer

Roche said its cancer drug Avastin showed positive results in the treatment of advanced ovarian cancer, further improving the prospects of one of the Swiss pharmaceutical company's best-selling drugs. (Source: WSJ.com: Health)

top  

  Intravitreal triamcinolone acetonide versus bevacizumab therapy for macular edema associated with branch retinal vein occlusion

Conclusions  IVTA and IVB injections were similarly effective for improving visual acuity in patients with macular edema secondary to BRVO. However, the IVTA group showed longer mean improvement duration and less disease recurrence, and required fewer injections than the IVB group. Content Type Journal ArticleCategory Retinal DisordersDOI 10.1007/s00417-010-1320-2Authors Yeo Jue Byun, Yonsei University College of Medicine The Institute of Vision Research, Department of Ophthalmology 134 Shinchon-dong, Sodaemoon-gu Seoul 120-752 KoreaMi In Roh, Yonsei University College of Medicine The Institute of Vision Research, Department of Ophthalmology 134 Shinchon-dong, Sodaemoon-gu Seoul 120-752 KoreaSung Chul Lee, Yonsei University College of Medicine The Institute of Vision...

top  

  Avastin phase III study shows positive results in women with advanced ovarian cancer

Roche announced today that a phase III study showed the combination of Avastin (bevacizumab) and chemotherapy followed by maintenance use of Avastin increased the time women with advanced ovarian cancer lived without their disease worsening (progression-free survival or PFS) compared to chemotherapy alone. A preliminary assessment of safety noted adverse events previously observed in pivotal trials with Avastin. Data from the study will be submitted for presentation at the 2010 American Society of Clinical Oncology (ASCO) annual meeting, June 4 to 8, 2010. (Source: Roche Media News)

top  

  Avastin phase III study shows positive results in women with advanced ovarian cancer

Roche announced today that a phase III study showed the combination of Avastin (bevacizumab) and chemotherapy followed by maintenance use of Avastin increased the time women with advanced ovarian cancer lived without their disease worsening (progression-free survival or PFS) compared to chemotherapy alone. A preliminary assessment of safety noted adverse events previously observed in pivotal trials with Avastin. Data from the study will be submitted for presentation at the 2010 American Society of Clinical Oncology (ASCO) annual meeting, June 4 to 8, 2010. (Source: Roche Investor Update)

top  

  Protective Effect of Intravitreal Bevacizumab and Sub-Tenon Triamcinolone Acetonide against Occlusion of Choriocapillaris Induced by Photodynamic Therapy

Ophthalmologica 2010;224:267–273 (DOI:10.1159/000287348) (Source: Ophthalmologica)

top  

  Genentech Announces Positive Results Of Avastin Phase III Study In Women With Advanced Ovarian Cancer

Genentech, Inc., a wholly owned member of the Roche Group, recently announced that a Phase III study showed the combination of Avastin (bevacizumab) and chemotherapy followed by maintenance use of Avastin alone increased the time women with previously untreated advanced ovarian cancer lived without the disease worsening (progression-free survival or PFS), compared to chemotherapy alone. (Source: Pharmaceutical Online News)

top  

  Phase III Study Of Avastin Plus Chemotherapy In Advanced Stomach Cancer Did Not Meet Primary Endpoint

Genentech, Inc., a wholly owned member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that a Phase III study (AVAGAST) did not meet its primary endpoint of showing Avastin® (bevacizumab) plus Xeloda® (capecitabine) or 5-FU and cisplatin chemotherapy extended the lives of people with inoperable or advanced stomach (gastric) cancer, compared to chemotherapy alone. Adverse events in the trial were consistent with those previously reported for Avastin and no new safety signals have been observed to date... (Source: Health News from Medical News Today)

top  

  Phase III Study Of Avastin Plus Chemotherapy In Advanced Stomach Cancer Did Not Meet Primary Endpoint

Genentech, Inc., a wholly owned member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that a Phase III study (AVAGAST) did not meet its primary endpoint of showing Avastin® (bevacizumab) plus Xeloda® (capecitabine) or 5-FU and cisplatin chemotherapy extended the lives of people with inoperable or advanced stomach (gastric) cancer, compared to chemotherapy alone... (Source: Cancer / Oncology News From Medical News Today)

top  

  Effects of intravitreal bevacizumab treatment on proliferative retinopathy in a patient with cerebroretinal vasculopathy

Content Type Journal ArticleCategory Letter to the editorsDOI 10.1007/s00415-010-5500-0Authors Marcus Kernt, Ludwig Maximilian University Department of Ophthalmology Mathildenstr. 8 80336 Munich GermanyAndreas Gschwendtner, Ludwig Maximilian University Department of Neurology Munich GermanyAljoscha S. Neubauer, Ludwig Maximilian University Department of Ophthalmology Mathildenstr. 8 80336 Munich GermanyMartin Dichgans, Ludwig Maximilian University Department of Neurology Munich GermanyChristos Haritoglou, Ludwig Maximilian University Department of Ophthalmology Mathildenstr. 8 80336 Munich Germany Journal Journal of NeurologyOnline ISSN 1432-1459Print ISSN 0340-5354 (Source: Journal of Neurology)

top  

  Update on systemic therapies of metastatic renal cell carcinoma

Conclusions  A range of potent drugs are available to patients with metastatic RCC. Treatment decisions should be made carefully taking into consideration that all targeted agents only have a palliative effect with prolongation of life, but do not cure metastatic RCC. Content Type Journal ArticleCategory Topic PaperDOI 10.1007/s00345-010-0519-5Authors E. Herrmann, University of Münster Department of Urology Albert-Schweitzer Strasse 33 48149 Münster GermanyS. Bierer, University of Münster Department of Urology Albert-Schweitzer Strasse 33 48149 Münster GermanyC. Wülfing, University of Münster Department of Urology Albert-Schweitzer Strasse 33 48149 Münster Germany Journal World Journal of UrologyOnline ISSN 1433-8726Print ISSN 0724-4983 (Source: World J...

top  

  Phase III study of bevacizumab plus chemotherapy in advanced gastric cancer fails to meet primary endpoint

Source: BioSpace Area: News According to a report featured by BioSpace, AVAGAST, a phase III study evaluating the effect of bevacizumab and capecitabine or 5-FU and cisplatin chemotherapy compared to capecitabine or 5-FU and cisplatin chemotherapy alone in 774 patients with gastric cancer, did not meet its primary endpoint of improved overall survival.   Data from the study will be submitted for presentation at the 2010 American Society of Clinical Oncology (ASCO) annual meeting, June 4 to 8, 2010. (Source: NeLM - News)

top  

  Genentech's Avastin fails stomach cancer trial

Genentech Inc.’s tumor-starving drug Avastin failed a late-stage trial in stomach cancer patients that could shave $400 million or more from parent company Roche’s long-term sales forecast. (Source: bizjournals.com Health Care:Biotechnology headlines)

top  

  Phase III Study of Avastin Plus Chemotherapy in Advanced Stomach Cancer Did Not Meet Primary Endpoint

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Feb 23, 2010 - Genentech, Inc., a wholly owned member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that a Phase III study (AVAGAST) did not meet its primary endpoint of showing... (Source: Drugs.com - Clinical Trials)

top  

  Phase III Study of Avastin Plus Chemotherapy in Advanced Stomach Cancer Did Not Meet Primary Endpoint

SOUTH SAN FRANCISCO, Calif.--(HSMN NewsFeed)--Genentech, Inc., a wholly owned member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that a Phase III study (AVAGAST) did not meet its primary endpoint of showing Avastin® (bevacizumab) p... Biopharmaceuticals, OncologyGenentech, Roche Group, Avastin, bevacizumab, stomach cancer (Source: HSMN NewsFeed)

top  

  Roche, Genentech Report Avastin Study Failure

From Associated Press (February 23, 2010) NEW YORK -- Genentech said Tuesday the combination of its blockbuster cancer drug Avastin and Xeloda did not meet a late-stage study goal of extending the lives of advanced stomach cancer patients. The... (Source: Drugs.com - Pharma News)

top  

  Roche's Avastin fails in stomach cancer trial

ZURICH (Reuters) - Roche Holding's cancer drug Avastin missed its main target in a late-stage trial when used with chemotherapy to treat patients with advanced stomach cancer, the Swiss drugmaker said on Tuesday. (Source: Reuters: Health)

top  

  Vascular Endothelial Growth Factor Polymorphisms: Role in Response and Toxicity of Tyrosine Kinase Inhibitors

Abstract  Angiogenesis is central to the growth of normal tissues and tumors. Inhibiting this pathway has been a strategy for drug development for tumors not responsive to most agents used in chemotherapy. Notably, signaling mediated by vascular endothelial growth factor (VEGF) is a key target because aberrant signaling via this pathway is frequently associated with neoangiogenesis in tumors. The drug-discovery effort to blunt VEGF signaling has led to the approval of bevacizumab and several receptor tyrosine kinase inhibitors (TKIs) that have shown efficacy in the clinical management of breast, colorectal, lung, and kidney cancer. Understanding the genetic variability in VEGF and VEGF receptor has led to identifying genotypic variations (single nucleotide polymorphisms [SN...

top  

  Bevacizumab Improves Pathological Response of Colorectal Cancer Liver Metastases Treated with XELOX/FOLFOX

Conclusions  Classifying histological response based on tumor regression grades qualifies to predict the outcome of patients with colorectal cancer liver metastases. Tumor regression grading provides a standardized pathological response evaluation, against which radiologic response on chemotherapy including biologicals can be prospectively evaluated. Content Type Journal ArticleCategory Colorectal CancerDOI 10.1245/s10434-010-0972-9Authors Markus Klinger, Medical University of Vienna Department of General Surgery, Hepatobiliary Service Vienna AustriaDietmar Tamandl, Medical University of Vienna Department of General Surgery, Hepatobiliary Service Vienna AustriaSandra Eipeldauer, Medical University of Vienna Clinical Institute of Pathology Vienna AustriaStefan Hacker,...

top  

  Combined phacoemulsification and viscogoniosynechialysis in the management of patients with chronic angle closure glaucoma

Abstract  The purpose of this study was to evaluate the effectiveness of phacoemulsification and viscogoniosynechialysis in the management of patients with chronic angle-closure glaucoma (CACG). Fifty-six eyes of 45 recruited patients were classified into two groups: group 1 had medically controlled CACG (IOP ≤ 21 mmHg) comprising 35 eyes and group 2 medically uncontrolled CACG (IOP > 21 mmHg with maximum tolerated medications) including 21 eyes. All of the patients had at least one quadrant without peripheral anterior synechia in gonioscopy. After phacoemulsification, a viscoelastic agent was used for viscogoniasynecialysis. Success was defined as IOP ≤ 21 mmHg with (relative success) or without (absolute success) medicati...

top  

  Roche, Genentech report study failure for Avastin combination aimed at stomach cancer

NEW YORK (AP) — Genentech said Tuesday the combination of its blockbuster cancer drug Avastin and Xeloda did not meet a late-stage study goal of extending the lives of advanced stomach cancer patients. The company, a unit of Switzerland's Roche,... (Source: OrlandoSentinel: Medical Research)

top  

  Avastin misses target for advanced stomach cancer

ZURICH (Reuters) - Roche Holding AG's cancer drug Avastin missed its main target in a late-stage trial when used with chemotherapy to treat patients with advanced stomach cancer, the Swiss drugmaker said on Tuesday. (Source: Reuters: Health)

top  

  Phase III study of Avastin plus chemotherapy in advanced stomach cancer did not meet primary endpoint

Roche announced today the topline results from a global phase III trial investigating the use of Avastin (bevacizumab) in combination with Xeloda (capecitabine) or fluorouracil and cisplatin chemotherapy in patients with inoperable, advanced or metastatic gastric cancer (stomach cancer). The study, known as AVAGAST, did not meet its primary endpoint of extending overall survival in patients treated with Avastin in combination with chemotherapy compared to the same chemotherapy plus placebo. (Source: Roche Media News)

top  

  Phase III study of Avastin plus chemotherapy in advanced stomach cancer did not meet primary endpoint

Roche announced today the topline results from a global phase III trial investigating the use of Avastin (bevacizumab) in combination with Xeloda (capecitabine) or fluorouracil and cisplatin chemotherapy in patients with inoperable, advanced or metastatic gastric cancer (stomach cancer). The study, known as AVAGAST, did not meet its primary endpoint of extending overall survival in patients treated with Avastin in combination with chemotherapy compared to the same chemotherapy plus placebo. (Source: Roche Investor Update)

top  

  Clinical course of advanced NSCLC patients experiencing hypertension during treatment with bevacizumab (ECOG 4599)

Source: JCO Area: News According to research published in the Journal of clinical Oncology, the onset of high blood pressure (HBP) during treatment with bevacizumab in combination with carboplatin and paclitaxel (PCB) may be associated with improved clinical outcomes among patients with advanced non-squamous non-small-cell lung cancer (NSCLC).   Because bevacizumab is postulated to decrease nitric oxide synthesis, leading to hypertension, which in turn may be a physiological sign that the VEGF pathway is more actively being blocked researchers evaluated whether patients showing signs of hypertension would be more likely to derive improved outcomes.   The ECOG 4599 was a phase III trial in which patients (n = 878) with advanced non-squamous NSCLC were randomly assigned to...

top  

  [Management of metastatic HER2-positive breast cancer: present and future.]

Authors: Guiu S, Coudert B, Favier L, Arnould L, Fumoleau P HER2-positive breast cancer accounts for 20 to 25% of breast cancers. The surexpression of this tyrosine-kinase receptor is often associated with a poor prognosis. However, the management and the outcome of these patients have changed these last ten years with trastuzumab. Despite the encouraging results obtained with this humanized monoclonal antibody directed against the HER2-receptor, used alone or in association with chemotherapy in metastatic patients, progression under trastuzumab are usually observed and resistances to this treatment are described. Thus, many other monoclonal antibodies and tyrosine-kinase inhibitors emerged. These therapeutics, used alone or in association with chemotherapy or trastuzumab have variable...

top  

  Lestaurtinib Enhances the Antitumor Efficacy of Chemotherapy in Murine Xenograft Models of Neuroblastoma.

CONCLUSIONS: We show that lestaurtinib can inhibit the growth of neuroblastoma both in vitro and in vivo and can substantially enhance the efficacy of conventional chemotherapy, presumably by inhibition of the Trk/brain-derived neurotrophic factor autocrine survival pathway. It may also enhance the efficacy of selected biological agents, but further testing is required to rule out unanticipated toxicities. Our data support the incorporation of Trk inhibitors, such as lestaurtinib, in clinical trials of neuroblastoma or other tumors relying on Trk signaling pathways for survival. Clin Cancer Res; 16(5); 1478-85. PMID: 20179224 [PubMed - as supplied by publisher] (Source: Clinical Cancer Research)

top  

  Comparative Profiling of the Novel Epothilone, Sagopilone, in Xenografts Derived from Primary Non-Small Cell Lung Cancer.

CONCLUSION: Analyses provided here show how preclinical studies can provide hypotheses for the identification of patients who more likely will benefit from new drugs as well as a rationale for combination therapies to be tested in clinical trials. Clin Cancer Res; 16(5); 1452-65. PMID: 20179216 [PubMed - as supplied by publisher] (Source: Clinical Cancer Research)

top  

  Bevacizumab: Colon perforation: 2 case reports

(Source: Reactions)

top  

  Second-line bevacizumab plus chemo improves PFS

The RIBBON-2 trial met its primary endpoint of prolonged progression-free survival. (Source: Cancer Network)

top  

  Bevacizumab Reduces Nose Bleeds in Inherited Condition

The vascular endothelial growth factor inhibitor bevacizumab administered by intranasal injection, or even by topical nasal spray, can effectively treat epistaxis from hereditary hemorrhagic telangiectasia, according to reports published in The Laryngoscope. (Source: Modern Medicine)

top  

  Bevacizumab-induced hand-foot syndrome: circumscribed type.

Authors: Munehiro A, Yoneda K, Nakai K, Demitsu T, Moriue T, Moriue J, Yokoi I, Fujita N, Matsuura N, Ishikawa S, Kubota Y PMID: 20184580 [PubMed - as supplied by publisher] (Source: The British Journal of Dermatology)

top  

  Choroidal Neovascularization in Pathologic Myopia: Intravitreal Ranibizumab Versus Bevacizumab—A Randomized Controlled Trial

Conclusion: This randomized clinical study cannot determine a statistically significant difference in anti-VEGF treatment effect between ranibizumab and bevacizumab for the treatment of CNV secondary to pathologic myopia. A larger study is required to determine the relative efficacy and duration of action of these drugs. (Source: American Journal of Ophthalmology)

top  

  A review of clinical trials of anti-VEGF agents for diabetic retinopathy

Conclusions  For diabetic macular edema, phase II trials of intravitreal pegaptanib and intravitreal ranibizumab have shown short-term benefit in visual acuity. Intravitreal bevacizumab also has been shown to have beneficial short-term effects on both visual acuity and retinal thickness. For proliferative diabetic retinopathy (PDR), early studies suggest that intravitreal bevacizumab temporarily decreases leakage from diabetic neovascular lesions, but this treatment may be associated with tractional retinal detachment (TRD). Furthermore, several studies indicate that bevacizumab is likely to prove a helpful adjunct to diabetic pars plana vitrectomy (PPV) for TRD. Finally, three small series suggest a potential beneficial effect of a single dose of bevacizumab to prevent wor...

top  

  Scientists At University of Texas Cancer Center Publish Research In Colon Cancer Therapy

A report, 'The evolving role of monoclonal antibodies in colorectal cancer: early presumptions and impact on clinical trial development,' is newly published data in The Oncologist. "Targeted biologic agents have an established role in treating metastatic colorectal cancer (mCRC). Bevacizumab, a recombinant monoclonal antibody against the vascular endothelial growth factor ligand is approved by the U.S.," scientists in the United States report. (Source: Cancercompass News: Colorectal Cancer)

top  

  [Hepatotoxicity of metastatic colorectal cancer chemotherapy: systematic review.]

ConclusionThe fact that irinotecan may be linked to an increased risk of hepatic failure and postoperative death, which is not the case of oxaliplatine, must be took in consideration in the choice of the preoperative chemotherapy before resection of hepatic metastasis of colorectal cancer. PMID: 20167564 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer)

top  

  [Mechanisms of resistance to molecular targeted therapies in breast cancer: update and future.]

Authors: Magné N, Chargari C, Conforti R, Toillon RA, Bauduceau O, Védrine L, Khayat D, Spano JP The importance of targeted therapies has been emphasized by clinical trials using antiangiogenic or HER2 inhibitors in breast cancer. First with trastuzumab, it was demonstrated that targeted therapies may improve outcome in patients with HER overexpressing breast cancer in metastatic or adjuvant settings. The emerging role for angiogenesis inhibitors has also been demonstrated with bevacizumab. Unfortunately, there is growing clinical and biological evidence that tumour cells may develop unexpected and complex mechanisms of resistance to those targeted therapies. This review outlines the mechanisms by which tumour cells may resist to new targeted agents. Most recent developments ...

top  

  Diffusion Magnetic Resonance Imaging Detects Pathologically Confirmed, Nonenhancing Tumor Progression in a Patient With Recurrent Glioblastoma Receiving Bevacizumab [DIAGNOSIS IN ONCOLOGY]

(Source: Journal of Clinical Oncology)

top  

  Clinical Course of Advanced Non-Small-Cell Lung Cancer Patients Experiencing Hypertension During Treatment With Bevacizumab in Combination With Carboplatin and Paclitaxel on ECOG 4599 [Thoracic Oncology]

Conclusion Data from ECOG 4599 suggest that onset of HBP during treatment with PCB may be associated with improved outcomes, and additional studies of the downstream effects of VEGF suppression and hypertension are needed. (Source: Journal of Clinical Oncology)

top  

  Effects of Bevacizumab on Apoptosis, Na + -K + -Adenosine Triphosphatase and Zonula Occludens 1 Expression on Cultured Corneal Endothelial Cells

Ophthalmic Res 2010;44:43–49 (DOI:10.1159/000286339) (Source: Ophthalmic Research)

top  

  Intracellular bevacizumab reduces phagocytotic uptake in RPE cells

Conclusions  The uptake of bevacizumab reduces phagocytosis in RPE cells, which indicates possible long-term effects of repeated bevacizumab treatment. Content Type Journal ArticleCategory Basic ScienceDOI 10.1007/s00417-010-1317-xAuthors Alexa Klettner, University of Kiel, Department of Ophthalmology Arnold-Heller-Str. 3, Haus 25 24105 Kiel GermanyFriederike Möhle, University of Kiel, Department of Ophthalmology Arnold-Heller-Str. 3, Haus 25 24105 Kiel GermanyJohann Roider, University of Kiel, Department of Ophthalmology Arnold-Heller-Str. 3, Haus 25 24105 Kiel Germany Journal Graefe's Archive for Clinical and Experimental OphthalmologyOnline ISSN 1435-702XPrint ISSN 0721-832X (Source: Graefe's Archive for Clinical and Experimental Ophthalmology)

top  

  Intravitreal injection of triamcinolone combined with bevacizumab for choroidal neovascularization associated with large retinal pigment epithelial detachment in age-related macular degeneration

Conclusion  Combined IVB and IVTA therapy seems to be an effective and safe procedure to treat CNV associated with large PED in AMD. Content Type Journal ArticleCategory Retinal DisordersDOI 10.1007/s00417-010-1302-4Authors Leila el Matri, Hedi Rais Institute of Ophthalmology Department B of Ophthalmology Boulevard 9 avril 1006 Bab saadoun Tunis TunisiaAhmed Chebil, Hedi Rais Institute of Ophthalmology Department B of Ophthalmology Boulevard 9 avril 1006 Bab saadoun Tunis TunisiaFadra Kort, Hedi Rais Institute of Ophthalmology Department B of Ophthalmology Boulevard 9 avril 1006 Bab saadoun Tunis TunisiaRym Bouraoui, Hedi Rais Institute of Ophthalmology Department B of Ophthalmology Boulevard 9 avril 1006 Bab saadoun Tunis TunisiaKarim Baklouti, Hedi Rais Institute of Op...

top  

  Comparison of Intravitreal Bevacizumab versus Triamcinolone for the Treatment of Diffuse Diabetic Macular Edema

Ophthalmologica 2010;224:258–264 (DOI:10.1159/000284466) (Source: Ophthalmologica)

top  

  Concentrations of unbound bevacizumab in the aqueous of untreated fellow eyes after a single intravitreal injection in humans

Conclusions: There are no pharmacological indications for a significant concentration of unbound bevacizumab in the anterior chamber of contralateral eyes in humans. (Source: Acta Ophthalmologica)

top  

  Microperimetric changes after intravitreal bevacizumab injection for exudative age-related macular degeneration

Conclusion: Intravitreal bevacizumab therapy induced a significant increase in mean retinal sensitivity and significant decrease in mean absolute scotoma size during 6 months. The MP1 microperimetry proved to be a valuable tool in the evaluation of functional benefit of exudative AMD therapy with intravitreal bevacizumab. (Source: Acta Ophthalmologica)

top  

  Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: A meta-analysis of randomized controlled trials.

Discussion. Treatment with bevacizumab may significantly increase the risk of cardiac ischemic events in cancer patients. PMID: 20156114 [PubMed - as supplied by publisher] (Source: Acta Oncologica)

top  

  Bevacizumab as a treatment option in advanced renal cell carcinoma: An analysis and ...

Beth Israel Deaconess Medical Center, Department of Medicine, Division of Hematology/Oncology, 375 Longwood Avenue, MS 428, Boston, MA 02215,... (Source: UroToday)

top  

  Bevacizumab: Thrombocytopenia during single-agent therapy: case report

(Source: Reactions)

top  

  The effect of bevacizumab on serum soluble FAS/FASL and TRAIL and its receptors (DR4 and DR5) in metastatic colorectal cancer

Conclusion  Non-significant changes in apoptotic markers with bevacizumab-based chemotherapy showed that they have no prognostic significance in MCRC patients. Significant change in sFAS/sFASL ratio according to treatment response could be an indicator of chemosensitivity. Content Type Journal ArticleCategory Original PaperDOI 10.1007/s00432-010-0803-1Authors Ramazan Yildiz, Gazi University Faculty of Medicine Department of Medical Oncology Besevler Ankara 06500 TurkeyMustafa Benekli, Gazi University Faculty of Medicine Department of Medical Oncology Besevler Ankara 06500 TurkeySuleyman Buyukberber, Gazi University Faculty of Medicine Department of Medical Oncology Besevler Ankara 06500 TurkeyAli Osman Kaya, Gazi University Faculty of Medicine Department of Medical Onco...

top  

  An Advance in Therapy for Patients With NSCLC

Does bevacizumab combined with pemetrexed and cisplatin provide improved efficacy in the treatment of non-small-cell lung cancer? Dr. Mark Kris examines the literature and answers this question. Medscape Hematology-Oncology (Source: Medscape Today Headlines)

top  

  New Treatment For Chronic Nose Bleeds

Patients suffering from hereditary hemorrhagic telangiectasia (HHT), an inherited vascular condition characterized by profuse nosebleeds, may find hope in a cancer-fighting drug called bevacizumab, also known as Avastin. "Bevacizumab is a drug used to treat cancers and eye disorders by restricting the growth of abnormal blood vessels," said Terence M. Davidson, MD, professor of surgery and director of the UC San Diego Nasal Dysfunction Clinic... (Source: Health News from Medical News Today)

top  

  New Treatment For Chronic Nose Bleeds

Patients suffering from hereditary hemorrhagic telangiectasia (HHT), an inherited vascular condition characterized by profuse nosebleeds, may find hope in a cancer-fighting drug called bevacizumab, also known as Avastin. "Bevacizumab is a drug used to treat cancers and eye disorders by restricting the growth of abnormal blood vessels," said Terence M... (Source: Ear, Nose and Throat News From Medical News Today)

top  

  Rebound tumour progression after the cessation of bevacizumab therapy in patients with recurrent high-grade glioma

Abstract  After withdrawal of bevacizumab in patients with recurrent high-grade glioma, we have observed a rapid tumour re-growth or “rebound” radiographic phenomenon with accelerated clinical decline. We retrospectively reviewed 11 patients treated at the Henry Ford Hermelin Brain Tumor Center with recurrent high-grade glioma who demonstrated a rebound progression pattern after the discontinuation of bevacizumab. The original tumour area-of-enhancement increased by a mean of 158%, when compared to the rebound magnetic resonance imaging. After rebound, no patients (0/8) showed a response to next-line treatments that did not include bevacizumab. The median survival of those re-treated with bevacizumab was 149 and 32 days for those who received other regimens. Abrupt...

top  

  Aqueous Humor Concentration of Bevacizumab After Subconjunctival Injection in Rabbit

Journal of Ocular Pharmacology and Therapeutics , Vol. 0, No. 0. (Source: Journal of Ocular Pharmacology and Therapeutics)

top  

  Long-Term Follow-Up After Multiple Intravitreal Bevacizumab Injections for Exudative Age-Related Macular Degeneration

Journal of Ocular Pharmacology and Therapeutics , Vol. 0, No. 0. (Source: Journal of Ocular Pharmacology and Therapeutics)

top  

  Intravitreal Bevacizumab (Avastin) in the Treatment of Macular Edema Associated With Perfused Retinal Vein Occlusion

Journal of Ocular Pharmacology and Therapeutics , Vol. 0, No. 0. (Source: Journal of Ocular Pharmacology and Therapeutics)

top  

  Adjunctive Intravitreal Bevacizumab-Combined Trabeculectomy Versus Trabeculectomy Alone in the Treatment of Neovascular Glaucoma

Journal of Ocular Pharmacology and Therapeutics , Vol. 0, No. 0. (Source: Journal of Ocular Pharmacology and Therapeutics)

top  

  Bevacizumab (Avastin) [PHARMACOLOGY VIGNETTE]

SUMMARY: Bevacizumab is a humanized monoclonal antibody that was the first FDA approved therapy designed to inhibit angiogenesis. This paper will review the mechanism of action and clinical role of this antiangiogenic agent. (Source: American Journal of Neuroradiology)

top  

  Conjugation of bevacizumab to cationic liposomes enhances their tumor-targeting potential

Nanomedicine , February 2010, Vol. 5, No. 2, Pages 181-192. (Source: Future Medicine: Nanomedicine)

top  

  Safety and Efficacy of First-line Bevacizumab With FOLFOX, XELOX, FOLFIRI and Fluoropyrimidines in Metastatic Colorectal Cancer: The BEAT Study

The Bevacizumab Expanded Access Trial (BEAT) evaluated the safety and efficacy of bevacizumab plus first-line chemotherapy in a general cohort of patients with metastatic colorectal cancer. Annals of Oncology (Source: Medscape Today Headlines)

top  

  Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL).

CONCLUSIONS: Final analysis of AVAiL confirms the efficacy of bevacizumab when combined with cisplatin-gemcitabine. The PFS benefit did not translate into a significant OS benefit, possibly due to high use of efficacious second-line therapies. PMID: 20150572 [PubMed - as supplied by publisher] (Source: Ann Oncol)

top  

  Bevacizumab: Nonarteritic anterior ischaemic optic neuropathy following intravitreal administration: case report

(Source: Reactions)

top  

  Bevacizumab: Intestinal perforation and peritonitis: 4 case reports

(Source: Reactions)

top  

  Bevacizumab May Benefit Choroidal Neovascularization

Intravitreal bevacizumab treatment produces superior results in treating juxtafoveal choroidal neovascularization secondary to pathologic myopia compared with laser treatment and photodynamic therapy, according to a pilot study published online Feb. 8 in the Archives of Ophthalmology. (Source: Modern Medicine)

top  

  [Delayed anastomotic dehiscence in advanced colorectal cancer treated with Bevacizumab.]

Authors: Placer C, Markinez I, Rodríguez A, Elósegui JL, Navascués JM PMID: 20149351 [PubMed - as supplied by publisher] (Source: Cirugia eEspanola)

top  

  Laser Photocoagulation, Photodynamic Therapy, and Intravitreal Bevacizumab for the Treatment of Juxtafoveal Choroidal Neovascularization Secondary to Pathologic Myopia [Clinical Sciences]

Conclusions  Overall, bevacizumab treatment offers the best functional results during a 2-year follow-up. In view of the small size of the sample in this study and the relatively low frequency of juxtafoveal choroidal neovascularization secondary to pathologic myopia, a multicentric clinical trial is necessary to validate our results.Published online February 8, 2010 (doi:10.1001/archophthalmol.2009.408). (Source: Archives of Opthalmology)

top  

  Avoiding Blood Clots During Treatment

One of the potential side effects of some types of chemotherapy is blood clots. Blood clots should be taken very seriously. If a blood clot occurs in an area of the body supplying blood to a vital organ, such as the lungs or brain, it can be life threatening. Some people are given blood thinners during treatment, specifically to head off a blood clot before it occurs. Fortunately, these medications are very effective. If you are taking blood thinners as part of your cancer care, you should take these medications exactly as prescribed. Bevacizumab + ESA = More Blood Clots New research has now identified a specific combination of cancer treatment medications that may increase the risk of blood clots. This is very important information. It can help your doctor determine whether you are at hig...

top  

  Pattern electroretinogram changes after intravitreal bevacizumab injection for diabetic macular edema

Abstract  We aimed at investigating the efficacy of intravitreal bevacizumab injection by evaluation of pattern electroretinogram (PERG) in diabetic patients with clinically significant macular edema (CSME). Thirty-five eyes of 35 patients with diabetes were treated with 2.5 mg of intravitreal bevacizumab injection as the primary therapy for CSME. The main outcome measures included best-corrected visual acuity, fundus fluorescein angiography, and P50 amplitudes of pattern electroretinogram (PERG) before and after intravitreal injection. Mean visual acuity improved significantly from a mean LogMAR value of 1.1 ± 0.2 at baseline to a maximum of 0.7 ± 0.3 after a mean follow-up time of 6.4 months. The mean baseline P50 and N95 amplitudes of PERG ...

top  

  Interstitial Pneumonitis after Treatment with Bevacizumab and Pegylated Liposomal Doxorubicin in a Patient with Metastatic Breast Cancer

Chemotherapy 2010;56:69–70 (DOI:10.1159/000282286) (Source: Chemotherapy)

top  

  Bevacizumab: When Is It Contraindicated in NSCLC Patients?

Patient selection for bevacizumab therapy has changed since its FDA approval. In this video blog, Dr. Mark Kris addresses the absolute and relative contraindications to the use of this drug. Medscape Hematology-Oncology (Source: Medscape Today Headlines)

top  

  A randomised trial of bevacizumab and reduced light dose photodynamic therapy in age-related macular degeneration: the VIA study

Conclusions Combination bevacizumab and 25 J/cm2 or 12 J/cm2 PDT significantly reduced the number of bevacizumab treatments required over 6 months. This study was powered to examine number of treatments, but not visual acuities. Nevertheless, visual acuities responded favourably in all three groups. Further studies will be helpful to explore visual outcomes. (Source: British Journal of Ophthalmology)

top  

  Low fluence rate photodynamic therapy combined with intravitreal bevacizumab for neovascular age-related macular degeneration

Conclusion The combination of IVB with low fluence PDT for the treatment of classic or predominantly classic neovascular AMD works in a synergistic fashion with a significant reduction in IVB reinjections rate. (Source: British Journal of Ophthalmology)

top  

  Glioblastoma: synergy of growth promotion between CCL5 and NK-1R can be thwarted by blocking CCL5 with miraviroc, an FDA approved anti-HIV drug and blocking NK-1R with aprepitant, an FDA approved anti-nausea drug

What is known and background: Two receptor signaling pathways that are commonly active in facilitating glioblastoma growth and invasion- that of CCR5 and neurokinin (NK)-1R- have small molecule inhibitors that are FDA approved and marketed to treat other conditions. The anti-HIV drug, maraviroc, inhibits human CCR5's ligand from binding, and hence blocks CCR5 stimulation. The anti-nausea drug aprepitant blocks substance P signaling at NK-1R.Aims and objective: We propose on the basis of molecular insights that a combination of the two drugs is likely to be useful in the treatment of glioblastoma.Comment: After stimulation by their respective ligands both CCR5 and NK-1R, through intermediaries, phosphorylate and thereby activate ERK1/2, triggering in turn migratory and mitotic events. Neuro...

top  

  Anti-Vascular Endothelial Growth Factor Therapies and Cardiovascular Toxicity: What Are the Important Clinical Markers to Target?

Conclusions. In anticipation of cardiovascular complications with anti-VEGF therapies, early detection and personalized management may improve clinical outcomes and tolerance. PMID: 20139170 [PubMed - as supplied by publisher] (Source: The Oncologist)

top  

  Intravitreal bevacizumab for surgical treatment of severe proliferative diabetic retinopathy

Conclusions  A preoperative intravitreal injection of bevacizumab may represent a new strategy for the surgical treatment of severe PDR by reducing retinal and iris neovascularization: this would make surgery much easier and safer, thus improving the anatomical and functional prognosis. According to our study, the best surgical results are achieved performing the IVB 7 days preoperatively. Content Type Journal ArticleCategory Retinal DisordersDOI 10.1007/s00417-010-1303-3Authors Raffaello di Lauro, Department of Ophthalmology, Hospital C.T.O. of Naples Naples ItalyPio De Ruggiero, Department of Ophthalmology, Hospital C.T.O. of Naples Naples ItalyRaffaella di Lauro, Department of Ophthalmology, Hospital C.T.O. of Naples Naples ItalyMaria Teresa di Lauro, Departmen...

top  

  Letrozole plus bevacizumab ‘feasible’ for metastatic breast cancer

Treatment with the aromatase inhibitior letrozole plus the anti-vascular endothelial growth factor antibody bevacizumab is feasible in postmenopausal patients with hormone receptor-positive metastatic breast cancer, US research shows. (Source: MedWire News - Oncology)

top  

  Letrozole plus bevacizumab ‘feasible’ for metastatic breast cancer

Treatment with the aromatase inhibitior letrozole plus the anti-vascular endothelial growth factor antibody bevacizumab is feasible in postmenopausal patients with hormone receptor-positive metastatic breast cancer, US research shows. (Source: MedWire News - Breast Cancer)

top  

  Drugs May Be Beneficial in Age-Related Macular Degeneration

In patients with exudative age-related macular degeneration, intravitreal bevacizumab or ranibizumab may help stabilize the loss of visual acuity, according to a study in the February issue of Ophthalmology. (Source: Modern Medicine)

top  

  Novel EphB4 Monoclonal Antibodies Modulate Angiogenesis and Inhibit Tumor Growth.

Authors: Krasnoperov V, Kumar SR, Ley E, Li X, Scehnet J, Liu R, Zozulya S, Gill PS EphB4 receptor tyrosine kinase and its cognate ligand EphrinB2 regulate induction and maturation of newly forming vessels. Inhibition of their interaction arrests angiogenesis, vessel maturation, and pericyte recruitment. In addition, EphB4 is expressed in the vast majority of epithelial cancers and provides a survival advantage to most. Here, we describe two anti-EphB4 monoclonal antibodies that inhibit tumor angiogenesis and tumor growth by two distinct pathways. MAb131 binds to fibronectin-like domain 1 and induces degradation of human EphB4, but not murine EphB4. MAb131 inhibits human endothelial tube formation in vitro and growth of human tumors expressing EphB4 in vivo. In contrast, MAb47 targets ...

top  

  Three-monthly intravitreal bevacizumab injections for neovascular age-related macular degeneration: short-term visual acuity results.

Conclusions. Three consecutive monthly injections of intravitreal bevacizumab to treat neovascular AMD is effective in improving VA in the short term. Longer prospective studies should be performed to confirm VA stability after the third injection. PMID: 20155704 [PubMed - as supplied by publisher] (Source: European Journal of Ophthalmology)

top  

  A phase II study of bevacizumab plus erlotinib for gemcitabine-refractory metastatic pancreatic cancer

Conclusions  The combination of bevacizumab and erlotinib is safe but relatively ineffective in patients with gemcitabine-refractory metastatic pancreatic cancer. Future studies should focus on refining subsets of patients in this challenging population likely to benefit from treatment beyond first-line. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00280-010-1257-5Authors Andrew H. Ko, University of California at San Francisco Helen Diller Family Comprehensive Cancer Center 1600 Divisadero Street, 4th Floor Box 1705 San Francisco CA 94115 USAAlan P. Venook, University of California at San Francisco Helen Diller Family Comprehensive Cancer Center 1600 Divisadero Street, 4th Floor Box 1705 San Francisco CA 94115 USAEmily K. Bergsland, University of C...

top  

  Highlights From February Ophthalmology

This month's Ophthalmology, the journal of the American Academy of Ophthalmology, includes results from a large Kaiser Permanente study of age-related macular degeneration (AMD) treatments, the first global report on retinal vein occlusion, and new recommendations to help elders with vision loss avoid falls. Kaiser Study Compares Effectiveness of Two AMD Drugs A Kaiser Permanente Southern California study compared two very similar medications - ranibizumab and bevacizumab - used to treat "wet" AMD and found the two equally effective at halting vision loss... (Source: Health News from Medical News Today)

top  

  Kaiser Study Compares Two AMD Treatments; "Eye Stroke" Prevalent Worldwide; New Data On Vision And Elders' Risk Of Falling

Results of a Kaiser Permanente study comparing two treatments for age-related macular degeneration (AMD), the first global report on retinal vein occlusion (RVO), and new recommendations to prevent falls in elders with vision loss are highlighted in this month's Ophthalmology, the journal of the American Academy of Ophthalmology. Kaiser Study Compares Effectiveness of Two AMD Drugs A Kaiser Permanente Southern California study compared two very similar medications - ranibizumab and bevacizumab-used to treat "wet" AMD and found the two equally effective at halting vision loss... (Source: Health News from Medical News Today)

top  

  BCNU for recurrent glioblastoma multiforme: efficacy, toxicity and prognostic factors

Conclusion: In summary, BCNU treatment appears to be a valuable therapeutic option for recurrent glioblastomas, where no other validated radio- and/or chemotherapy are available. (Source: BMC Cancer)

top  

  Photodynamic therapy for choroidal neovascularization in young adult patients

We report our experience with photodynamic therapy (PDT) in the treatment of choroidal neovascularization (CNV) in young adult patients. This was a retrospective study of young adults with CNV treated with PDT. Data collected included age, diagnosis, type and size of CNV, number of treatments, visual outcome, and side effects. Ten patients (11 eyes) were included in the study (mean age 27.2 ± 13.3 years). Etiologies included multifocal choroiditis (3 eyes), idiopathic CNV (5 eyes), central serous chorioretinopathy (1 eye), and toxoplasma (2 eye). The mean number of treatments was 2 ± 0.7 and the mean follow-up time was 13.1 ± 9.5 months. Initial visual acuity (VA) ranged from 20/25 to 20/1,200 (mean logMAR 0.6 ± 0.5), and improved ...

top  

  Bevacizumab: In Previously Treated Glioblastoma

(Source: Drugs)

top  

  Triple therapy for neovascular age-related macular degeneration (verteporfin photodynamic therapy, intravitreal dexamethasone, and intravitreal bevacizumab).

Conclusions: By combining agents with complementary mechanisms of action, triple therapy could maintain visual acuity and macular anatomy while allowing a reduction in the number of anti-vascular endothelial growth factor injections required. PMID: 20130708 [PubMed - in process] (Source: Canadian Journal of Ophthalmology)

top  

  Effect of subconjunctival and intraocular bevacizumab injections on corneal neovascularization in a mouse model.

Conclusions: Bevacizumab injections partially inhibit the growth of corneal neovascularization induced by acute chemical injury in a mouse model. The intraocular routes of injection were found to be the most effective, and the subconjunctival route of injection yielded the earliest peak response. PMID: 20136420 [PubMed - in process] (Source: Current Eye Research)

top  

  Intravitreal bevacizumab in treatment of idiopathic persistent central serous chorioretinopathy: a prospective, controlled clinical study.

Conclusions: Our results indicate that intravitreal bevacizumab injection may be a new, promising treatment option for select patients with idiopathic persistent central serous chorioretinopathy. Continued studies with intravitreal bevacizumab in this population will help to establish its long-term efficacy. PMID: 20136418 [PubMed - in process] (Source: Current Eye Research)

top  

  Molecular basis for the treatment of renal cell carcinoma

Abstract  Renal cell carcinoma (RCC) is a heterogeneous malignancy whose incidence rate has notably increased in recent years without any evident reason. Traditionally, RCC has been resistant to classic treatments (chemotherapy, radiotherapy and hormonal therapy), with only a small percentage of patients benefiting from cytokine therapy. Different hereditary syndromes have been associated with RCC, Von Hippel Lindau (VHL) being the most important syndrome. Understanding key molecular pathways implicated in the tumorigenesis of RCC has crystallised in the development of more effective therapies. Specifically, drugs targeting VEGF (bevacizumab, sunitinib, sorafenib, axitinib, pazopanib) and PI3K-mTOR (temsirolimus and everolimus) have become the cornerstone of renal cancer tr...

top  

  Advances in Target Therapy for Lung Cancer

Recent progress in molecular biology has shown that cancer cells acquire common phenotypes such as self-sufficiency of growth signals, resistance to anti-proliferative and apoptotic signals through the accumulation of genetic and epigenetic changes. Recently developed anticancer drugs target these molecular mechanisms and good results have been reported for various cancer types. In lung cancer, tyrosine kinase inhibitors specific for the epidermal growth factor receptor such as gefitinib and erlotinib have changed clinical practice dramatically. About half of the Japanese patients with lung cancers harbor an activating mutation of the epidermal growth factor receptor gene and they are very sensitive to epidermal growth factor receptor tyrosine kinase inhibitors. Progression-free survival o...

top  

  A phase I study of axitinib (AG-013736) in combination with bevacizumab plus chemotherapy or chemotherapy alone in patients with metastatic colorectal cancer and other solid tumors

Conclusion: Axitinib is well tolerated in combination with FOLFOX, FOLFIRI, or FOLFOX plus 2 mg/kg bevacizumab. PK interactions appear to be absent. (Source: Annals of Oncology)

top  

  North Central Cancer Treatment Group (NCCTG) N0432: phase II trial of docetaxel with capecitabine and bevacizumab as first-line chemotherapy for patients with metastatic breast cancer

Conclusion: TX-BV demonstrated significant activity; dose modifications were required to manage drug-related toxic effects. (Source: Annals of Oncology)

top  

  Bevacizumab-induced Hypovascular Hepatocellular Carcinoma Treated by Transarterial Chemoembolization in a Patient with Metastatic Colon Cancer

The angiogenesis of hepatocellular carcinoma (HCC) is mediated by growth factors, particularly vascular endothelial growth factor (). Serum vascular endothelial growth factor levels in patients with HCC correlate with malignant behavior and clinical outcomes (). Early clinical studies have shown that the anti–vascular endothelial growth factor antibody bevacizumab might be able to deregulate angiogenesis in HCC (). Angiogenesis inhibited by bevacizumab appears as a significant reduction in tumor enhancement on computed tomography (CT) perfusion () and dynamic contrast-enhanced magnetic resonance images (). Here, we treated a patient with histopathologically proven HCC and metastatic colon cancer by transarterial chemoembolization before and after chemotherapy with bevacizumab. (Source: J...

top  

  Feasibility Trial of Letrozole in Combination With Bevacizumab in Patients With Metastatic Breast Cancer [Breast Cancer]

Conclusion Combination letrozole and bevacizumab was feasible with expected bevacizumab-related events of hypertension, headache, and proteinuria. Phase III proof-of-efficacy trials of endocrine therapy plus bevacizumab are in progress (Cancer and Leukemia Group B 40503). (Source: Journal of Clinical Oncology)

top  

  Phase II Trial of Pemetrexed Plus Bevacizumab for Second-Line Therapy of Patients With Advanced Non-Small-Cell Lung Cancer: NCCTG and SWOG Study N0426 [Thoracic Oncology]

Conclusion The study did not meet its primary end point. However, the median PFS time of 4 months is promising. Pharmacogenetic studies in larger cohorts are needed to definitively identify polymorphisms that predict for survival and toxicity of pemetrexed. (Source: Journal of Clinical Oncology)

top  

  Underused Bevacizumab Adds Benefit to NSCLS Chemotherapy Protocols

Bevacizumab continues to improve outcomes in patients with non-small cell lung cancer. In this video blog, Dr. Mark Kriss describes new findings that support its use as a standard of care. Medscape Hematology-Oncology (Source: Medscape Today Headlines)

top  

  Is there an advantage to administering bevacizumab directly to brain tumors using microcatheters?

(Source: Clinical Trials And Noteworthy Treatments For Brain Tumors)

top  

  Is there an advantage to administering bevacizumab directly to brain tumors using microcatheters?

(Source: Clinical Trials And Noteworthy Treatments For Brain Tumors)

top  

  Is there an advantage to administering bevacizumab directly to brain tumors using microcatheters?

(Source: Clinical Trials And Noteworthy Treatments For Brain Tumors)

top  

  Is there an advantage to administering bevacizumab directly to brain tumors using microcatheters?

(Source: Clinical Trials And Noteworthy Treatments For Brain Tumors)

top  

  Is there an advantage to administering bevacizumab directly to brain tumors using microcatheters?

(Source: Clinical Trials And Noteworthy Treatments For Brain Tumors)

top  

  Is there an advantage to administering bevacizumab directly to brain tumors using microcatheters?

(Source: Clinical Trials And Noteworthy Treatments For Brain Tumors)

top  

  Is there an advantage to administering bevacizumab directly to brain tumors using microcatheters?

(Source: Clinical Trials And Noteworthy Treatments For Brain Tumors)

top  

  Is there an advantage to administering bevacizumab directly to brain tumors using microcatheters?

(Source: Clinical Trials And Noteworthy Treatments For Brain Tumors)

top  

  Is there an advantage to administering bevacizumab directly to brain tumors using microcatheters?

(Source: Clinical Trials And Noteworthy Treatments For Brain Tumors)

top  

  Is there an advantage to administering bevacizumab directly to brain tumors using microcatheters?

(Source: Clinical Trials And Noteworthy Treatments For Brain Tumors)

top  

  Is there an advantage to administering bevacizumab directly to brain tumors using microcatheters?

(Source: Clinical Trials And Noteworthy Treatments For Brain Tumors)

top  

  Is there an advantage to administering bevacizumab directly to brain tumors using microcatheters?

(Source: Clinical Trials And Noteworthy Treatments For Brain Tumors)

top  

  Is there an advantage to administering bevacizumab directly to brain tumors using microcatheters?

(Source: Clinical Trials And Noteworthy Treatments For Brain Tumors)

top  

  Is there an advantage to administering bevacizumab directly to brain tumors using microcatheters?

(Source: Clinical Trials And Noteworthy Treatments For Brain Tumors)

top  

  Is there an advantage to administering bevacizumab directly to brain tumors using microcatheters?

(Source: Clinical Trials And Noteworthy Treatments For Brain Tumors)

top  

  Is there an advantage to administering bevacizumab directly to brain tumors using microcatheters?

(Source: Clinical Trials And Noteworthy Treatments For Brain Tumors)

top  

  Is there an advantage to administering bevacizumab directly to brain tumors using microcatheters?

(Source: Clinical Trials And Noteworthy Treatments For Brain Tumors)

top  

Top Viagra Store

A first shop in the series of one-pill shops is rightfully viagra-targeted. The index page offers only Viagra, both generic and original.It is possible to purchase other ED products from other pagers, but the main accent is on Viagra.

top-viagra-store.com

Indian Meds

A most recent indian-themed, ethnic site. Includes generic and original (brand) products. al our standard navigational tools and support options are available. This site converts nicely on general pharmaceutical traffic as it has products for vurtually any need.

indianmeds.org

Friendly ED Pharmacy

Many ED customers are anxious about the status their orders. This special friendly site is here to solve the problem. "State of the art" design features high usability and clearly visible support options. All this helps to satisfy even the most demanding customer and results in increased sales ratio.

friendly-ed-pharmacy.com

Popular ED Products

This ED site offers simplistic design that gets right to the point - this IS the site for ED. Popular ED list the top selling products and converts best on ED-targeted, pill-specific traffic.

popular-ed-products.com

Perfect ED Store

This site is just right for ED customers. All ED products are conveniently listed at main page, allowing to make an easy choice. Our regular Sample Pills Offer is emphasized here. Customers can try new products and are likely to return for more refills.

perfect-ed-store.com

Worlds Best Pharmacy

The name says it all. This is the best online pharmacy on the web. The index page is set to show the most polular ED products, while the menu and quicksearch allow to find products in other categories.

worlds-best-pharmacy.com

Delhi Drugs

This Indian-themed site offers a completely new design. All our generic products are availabe and can easily be located with the help of quicksearch feature. Includes our latest shopping engine and billing page.

www.delhi-drugs.com

Indian Generics

Many customers are looking for Indian drugs, and this site is designed specifically for such customers. It includes many generic products, modern design, translated into 7 languages and prices in both USD and Euros. Also it uses our latest shopping engine and billing page.

www.indian-generics.com